Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou BlueHorse Biotechnology is a specialized biotechnology company focused on the development and application of droplet microfluidic technology for high-throughput screening and single-cell analysis. The company provides an integrated platform that combines proprietary microfluidic chips, automated instrumentation, and specialized reagents to accelerate the discovery of monoclonal antibodies and the development of high-efficiency cell lines. Their core technology allows for the screening of millions of cells in a single day, enabling the identification of rare functional candidates that traditional methods might miss. BlueHorse Biotechnology primarily serves the biopharmaceutical and synthetic biology sectors, offering solutions that significantly reduce R&D timelines and costs. The company is headquartered in the Suzhou Industrial Park, a major hub for biotech innovation in China.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Suzhou BlueHorse Biotechnology.